Abstract Epithelial-mesenchymal transition (EMT) is regulated by interaction of carcinoma and stromal cells and crucial for progression of urinary bladder carcinoma (UBC). Therefore, the influence of activated fibroblasts on the expression of E-cadherin repressors as well as EMT and invasion in UBC was investigated. A correlative analysis of the immunohistochemical expression of fibroblast (ASMA, S100A4, FAP, SDF1, PDGFRb) and EMT (Snail, Slug, Zeb1, E-cadherin) markers was performed on 49 UBC cases of different stages. The impact of distinguishable growth factor stimulated fibroblasts on invasion, EMT, and E-cadherin repressor expression was investigated in an invasion model. In situ, invasiveness was significantly correlated to the loss of membranous E-cadherin (E-cad_m) and increased Snail, Slug, Zeb1 in tumour cells, as well as to increased ASMA, S100A4, and PDGFRb in stromal cells. A significant correlation to nodal metastasis could be evidenced for the loss of E-Cad_m, and for an increase in S100A4 and PDGFRb. Comparison of stromal and EMT markers revealed significant correlations of ASMA to Snail and Slug; of S100A4 to the loss of E-cad_m and Zeb1; and of PDGFRb to the loss of E-Cad_m, Slug and Zeb1. In vitro, TGFb1 induced myofibroblasts were the strongest attractants, while aFGF or TGFb1/aFGF stimulated fibroblasts were the most potent EMT inductors. As shown here for the first time, distinct sub-populations of fibroblasts are to various extents associated with EMT and tumour progression in UBC. These relevant findings might be the basis for the identification of new diagnostic markers and therapeutic targets selectively affecting tumour supporting CAF effects.
Introduction
Urothelial carcinoma of the urinary bladder (UBC) is the most common malignant epithelial tumour of the human bladder. During tumour progression, growth behaviour varies from papillary non-muscle invasive up to muscle invasive stages. Superficial tumours tend to reappear after removal by transurethral resection (TUR) and will rarely develop an invasive phenotype. More aggressive tumours start as high-grade carcinoma in situ or as de novo invasive tumours with high metastatic rates and poor prognosis Electronic supplementary material The online version of this article (doi:10.1007/s00418-012-0998-0) contains supplementary material, which is available to authorized users. (Jost 2003) . Differences between non-invasive and invasive tumours are especially represented by the molecular profile of the different carcinoma cells. Low-grade noninvasive tumours are characterized by the occurrence of activating mutations in the HRAS and the fibroblast growth factor receptor 3 genes, whereas the high-grade invasive tumours show structural and functional defects in the p53 and retinoblastoma protein pathways (Wu 2005) .
Besides the genetically caused varieties in UBC cell behaviour, there is a crucial role of epigenetic regulators within the process of invasive tumour cell phenotype development. There is rising evidence that epithelial-tomesenchymal transition (EMT) in invasive tumour areas seems to play a pivotal role in the formation of invasive and metastatic cell types. The process of EMT is known to be crucial in embryonic development as well as tissue regeneration and becomes reactivated during tumour progression (Iwano et al. 2002) . EMT is characterized by the loss of epithelial markers and cell-cell contacts followed by the re-expression of mesenchymal proteins and the formation of a migratory phenotype. In particular, the loss of E-cadherin induced by several transcriptional repressors like Snail, Slug and Zeb, and the de novo expression of N-cadherin or P-cadherin are known to be associated with EMT also in invasive and metastatic UBC (Lascombe et al. 2006; Bryan et al. 2008) . Inducible EMT effects could be evidenced for different bladder carcinoma cell lines (Boyer et al. 1989) . Moreover, increasing mesenchymal attributes show correlations with clinical parameters like grading and staging known to be associated with a poor prognosis (Baumgart et al. 2007) . EMT is also of special interest with respect to innovative tumour targeting therapy strategies. In vitro studies could prove a correlation between the EMT phenotype and the phenomenon of drug resistance (McConkey et al. 2009 ). Against that background, deeper insights into the molecular mechanisms of EMT regulation are of high clinical and potential therapeutic interest.
The formation of a mesenchymal tumour cell phenotype is considered to be a complex process regulated by a variety of growth factors like TGFb1 (Siegel and Massague 2003) or different chemokines, e.g. stromal derived factor 1 (SDF-1 or CXCL12) (Allinen et al. 2004 ). For example, TGFb1 affects a loss of E-cadherin and cytokeratin, an increased expression of mesenchymal markers and an actin reorganization resulting in enhanced cell motility in breast cancer cells (Piek et al. 1999) . EGF and TGFa could be proven to be EMT inducers in human bladder carcinoma cell lines (Cattan et al. 2001) . Especially the interaction of tumour cells and activated stromal fibroblasts has a considerable influence on growth factor driven tumour phenotype development and EMT (van Zijl et al. 2009 ).
Quiescent fibroblasts become activated through mutual paracrine effects with tumour cells. Activated fibroblasts, also known as cancer-associated fibroblasts (CAFs), are similar to myofibroblasts which occur during tissue repair and are characterized by the expression of alpha smooth muscle actin (ASMA) as well as their enhanced motility (Ronnov-Jessen et al. 1995) . In contrast to fibroblasts occurring in wound healing, CAFs are continuously activated and have lost their ability to pass through apoptosis (De Wever and Mareel 2002) . CAFs support malignant transformation and invasiveness of tumour cells (Bhowmick et al. 2004 ). They subsume a heterogeneous cell population with regard to their different origins as well as a variable marker profile (Sugimoto et al. 2006) . ASMA expression is the most popular attribute of CAFs and also of clinical importance. An increase in ASMA-positive fibroblasts has been reported to be associated with tumour progression and invasiveness not only in UBC (Nimphius et al. 2007 ). Other differentially expressed CAF markers which have been evidenced to be associated with prognosis include fibroblast-specific protein 1 (FSP1 or S100A4), fibroblast activation protein (FAP or seprase), and PDGFRb (Ö stman and Augsten 2009) as well as SDF1 (Franco et al. 2011) . Although an influence on EMT is postulated, the functional importance of the different fibroblast phenotypes characterized by these markers for cancer cell phenotype modulation is not fully understood up to now.
A detailed investigation and definition of different CAF sub-populations by expression analysis of important CAF markers available from the literature has not been performed for UBC until now. Furthermore, a correlation of these CAF markers to the tumour biological behaviour as well as to a panel of markers crucial for EMT is innovative and will significantly contribute to a deeper understanding of UBC progression. This might be of high clinical relevance because the elucidation of functionally different CAF subpopulation with regard to their tumour growth supporting impact could be the basis for (1) the development of new diagnostic and prognostic markers and (2) the identification of new CAF-based therapeutic targets to selectively affect the individual tumour microenvironment.
Therefore, the aim of the current study was to describe the influence of activated fibroblasts on EMT phenomena in UBC in situ and in vitro. A correlative analysis on the immunohistochemical expression of fibroblast activation and EMT markers was performed on routine tumour tissue material. Furthermore, the impact of fibroblasts stimulated by different growth factors on the invasive potential and phenotype transition of UBC cells was investigated in cell culture.
Materials and methods

Tissue material
49 formalin-fixed and paraffin-embedded tissue samples of urothelial carcinoma of the urinary bladder exhibiting different tumour stages were available. A summary of the grading and staging data is given in supplementary material table S1. Cases included 14 9 Ta tumours (all of them resected by TUR) and 35 9 T1-4 tumours (5 of them resected by TUR, 30 cystectomy specimens). The histological diagnoses were established according to the WHO classification criteria (Eble et al. 2004) . Ethical approval was obtained from the local Research Ethic Committee.
Immunohistochemistry
The immunohistochemical staining for EMT markers (E-cadherin, Slug, Snail, Zeb1) and stromal activation markers (ASMA, FAP, SDF1, S100A4, PDGFRb) was performed using the DAKO Real TM Detection System, Alkaline Phosphatase/Red, Rabbit/Mouse (DakoCytomation, Hamburg, Germany) according to the instructions of the manufacturer. Primary antibodies, appropriate dilution and pre-treatment are given in Table 1 . Blocking of endogenous biotin was done using the Biotin Blocking System (DakoCytomation, Hamburg, Germany). For negative control, the primary antibody was replaced by nonimmune serum. After rinsing in water, sections were counterstained with haematoxylin and mounted.
Semiquantitative evaluation of immunohistochemical marker expression
Semiquantitative evaluation of immunohistochemical staining was done by light microscopy (Axiophot 2 MOT, Zeiss, Oberkochen, Germany). For EMT markers, the decoration of stromal cells (s), of the cytoplasm (c) and/or nucleus (n) of tumour cells as well as the membranous staining (m) in case of E-cadherin were differentially assessed. In case of stromal activation markers, the staining of stromal cells (s) and of tumour cells (t) was evaluated. The following scoring system was used for semiquantitative analysis of the reactivity in the tumour area in the tissue section: 0 = no staining, 1 = only few strongly positive cells or delicate staining of larger areas of the investigated compartment, 2 = partial strong staining of tumour or stromal cells or moderate staining of larger areas Spearman-Rho rank analysis was performed to evaluate the correlation of the markers among one another.
Cell lines
The UBC cell line RT112 (G2, DSMZ ACC 418) and the human telomerase-immortalized fibroblasts hTERT-BJ1 (Clontech Laboratories, Inc., Mountain View, California, USA) were available for cell culture experiments. Cells were grown and maintained at 37°C 5 % CO 2 and 92 % humidity in RPMI 1640 (RT112) and IMDM (hTERT-BJ1) nutrient medium supplemented with 10 % FCS (all media were derived from GIBCO Invitrogen Corp. Carlsbad, California, USA).
Immunocytochemistry
For immunocytochemistry, tumour cells or fibroblasts (stimulated or non-stimulated, see below) were seeded on cell culture slides (BD Falcon Ò , BD Biosciences, Franklin Lakes, New Jersey, USA) and cultured until subconfluence. In the next step, cells were fixed in acetone/methanol 1:1 and stored at -20°C until further analyses. Immunocytochemistry was performed as described for immunohistochemistry but without pre-treatment.
In vitro model of activated fibroblast phenotypes
The different phenotypes of activated fibroblasts were generated by growth factor stimulation of hTERT-BJ1 fibroblasts. Stimulation was performed in cell culture slides (2.5 9 10 4 fibroblasts in 8-well cell culture slides, start of stimulation after 24-h cultivation) for immunocytochemistry and in 24-well plates (1 9 10 5 fibroblasts per well, start of stimulation after 48-h cultivation) for mRNA expression analysis. After starving for 4 h in 0 % FCS/medium, stimulation took place for 3 days with daily renewing of medium and growth factors. For stimulation, TGF-b1 (Gibco Ò , Invitrogen Corporation, Carlsbad, Californien; USA) and aFGF (Gibco Ò , Invitrogen Corporation, Carlsbad, Californien; USA) were used in a final concentration of 10 ng/ml and PDGF-AB (Gibco Ò , Invitrogen Corporation, Carlsbad, Californien; USA) in a final concentration of 50 ng/ml IMDM/0.5 % FCS. For co-stimulation, 10 ng/ml of TGF-b1 and aFGF were used respectively. A negative control without growth factor stimulation was included in each experiment. Cells were fixed for immunocytochemistry, harvested for invasion assay experiments, or stimulation was terminated for the extraction of mRNA by adding RLT buffer according to the guidelines of the manufacturer (component of the RNeasy Mini Kit, Qiagen GmbH, Hilden, Germany).
Invasion assay using pre-stimulated fibroblasts as attractant cells Fibroblasts, pre-stimulated as described above, were used as attractant cells for invasion assays of 1 9 10 5 urothelial tumour cells (RT112) seeded on top of a Boyden chamber system (8-lm pores, BD Bioscience, Franklin Lakes, New Jersey, USA). After pre-stimulation of fibroblasts in the lower chamber of the invasion system, the medium containing growth factors was carefully washed away. Inserts were incubated with 80 ll of a 1:3 diluted BD Matrigel TM (growth factor reduced; BD Bioscience, Franklin Lakes, New Jersey, USA) serum-free medium (IMDM) mixture for 30 min. After an invasion time of 48 h, the non-invaded RT112 cells were removed from the upper side of the membrane. After paraformaldehyde fixation and haematoxylin staining, the insert membrane was mounted with pertex. Quantification of the invaded cells from the lower chamber side was performed by computer-aided image analysis (AxioVision Release 4.6, Zeiss, Oberkochen, Germany) of five randomly taken images using a 109 objective. Results were presented as mean value and standard deviation.
For RT-PCR, the non-invasive cells (upper chamber side) and the invaded tumour cells (lower chamber side) were separately wiped off the membrane with cotton swabs. Swabs were transferred to the lysis buffer of the RNeasy Micro Kit (Qiagen GmbH, Hilden, Germany) and RNA isolation was performed as recommended by the manufacturer. All experiments were performed in triplicate.
Real-time PCR's Total RNA was extracted from cell culture experiments using the RNeasy Mini Kit or Micro Kit (Qiagen GmbH, Hilden, Germany) following the manufacturer's instructions, eluted in 50-ll RNase-free water and stored at -80°C. mRNA levels were determined by means of QuantiTect SYBR green real-time one-step RT-PCR kit (Qiagen GmbH, Hilden, Germany) as recommended by the manufacturer. Primer and annealing temperatures are listed in Table 2 . Amplification and detection of specific products were performed using the Bio-Rad MyiQ real-time PCR system (Bio-Rad Laboratories GmbH, München, Germany) using the following cycle profile: 1 cycle of 50°C for 30 min, 1 cycle of 95°C for 15 min, 40 cycles of 94°C for 15 s, annealing temperature for 30 s, followed by 72°C for 30 s. In a next step, melting curves were generated as follows: 1 cycle of 95°C for 1 min, 1 cycle of 55°C for 30 s, and 82 cycles of heating from 55°C to 95.5°C for 10 s each in 0.5°C steps.
To avoid amplification of cellular DNA at least one primer spans an intron-exon boundary. The threshold method was used for quantification of the mRNA level. Cycle threshold change (DCt) values were calculated based on the internal standard GAPDH. Results are presented as 40-DCT values or as ''fold change'' in comparison to control (2 -DDCt /DDCt method). Results were presented as mean value and standard error of the mean.
Results
Immunohistochemical expression of stromal and EMT markers in UBC E-cadherin immunostaining could be detected exclusively in urothelial and carcinoma cells. In general, adjacent normal urothelium and superficial carcinomas showed a more or less homogenous membranous expression, whereas invasive carcinomas are characterized by a heterogeneous pattern in terms of its membranous E-cadherin decoration. In the majority of the invasive tumour samples, a diminution or loss of membranous E-cadherin in tumour cells could be observed in spatial association to the invasive front of budding tumour areas or to disseminated tumour growth (Fig. 1a) . Nevertheless, there were few samples in which also high-invasive tumour cell populations exhibited a strong membranous immunohistochemical expression of E-cadherin (Fig. 1b) . Cytoplasmic E-cadherin staining could also be detected but seems not to be related to tumour biological behaviour. Slug could be detected in the suburothelial stroma, in smooth muscle cells, and in areas of inflammation including granulation tissue. Carcinoma cells preferentially showed a cytoplasmic staining pattern with a pronunciation of the invasive areas-nuclear staining of tumour cells only rarely occurred. Moreover, intratumoural fibro-/myofibroblasts are strongly stained (Fig. 1c) . Nuclear Snail was detectable in urothelial cells, tumour vessels as well as carcinoma cells, stromal staining was rare. In addition, carcinoma cells often showed a strong cytoplasmic decoration (Fig. 1d) .
The antibody against Zeb1 marked cells of suburothelial connective tissue, stromal cells of UBC and the cytoplasm of carcinoma cells. Nuclear staining of tumour cells was seldom but clearly detectable (Fig. 1e) .
ASMA could be observed in smooth muscle cells of different localization, vessels, and in the carcinoma stroma (Fig. 2a) . FAP showed a heterogeneous expression in tumour and stromal cells with mostly a cytoplasmic staining pattern (Fig. 2b) . Moreover, FAP positive muscle and urothelial cells could be observed. SDF-1 was strongly Fig. 1 Immunohistochemical detection of EMT markers on paraffin sections of urothelial carcinoma of the urinary bladder. Demonstration a of the loss of membranous E-cadherin in the invasive front of a budding tumour area (T4a/G2 carcinoma) and b of a high-invasive tumour cell populations which strongly expressed the protein in the plasma membrane (T4a/G3 carcinoma). The E-cadherin repressors Slug, Snail, und Zeb1 show different expression in the stroma, in the tumour cell cytoplasm, and/or in the tumour cell nuclei: c decoration of Slug in tumour cell cytoplasm in the invasive front with some strongly stained fibro-/myofibroblasts (T4a/G3 carcinoma), d demonstration of Snail in the tumour cell nuclei and cytoplasm (T4a/G2 carcinoma), and e rare nuclear Zeb1 staining of tumour cells (T3a/G3 carcinoma). f Staining control (invasive area of a T2a/G2 carcinoma), (hematoxylin counter staining, bars 100 lm in a and f, 50 lm in b-e) expressed in endothelial, urothelial and carcinoma cells with heterogeneous patterns. There is nearly no staining observable in stromal cells (Fig. 2c) . S100A4 could be detected at different quantitative levels in urothelial cells, tumour cells, and also in lymphocytes. The staining pattern was nuclear or cytoplasmatic. Furthermore, in the tumourassociated stroma sporadic-positive fibroblasts were detectable (Fig. 2d) . PDGF-receptor b occurred in stromal fibroblasts and in tumour vessels and could also be shown in association to inflammation and granulation tissue as well (Fig. 2e) .
Semiquantitative evaluation of immunohistochemical marker expression and correlative analyses
The results of semiquantitative analysis of immunohistochemical marker expression are summarized in table S1. To test for statistically significant differences of the semiquantitative immunohistochemical marker expression levels between the different conditions of invasiveness (noninvasive vs. invasive and non-muscle invasive vs. muscle invasive) and the occurrence of metastases, the Fisher exact test was used. The corresponding p values are provided as Fig. 2 Immunohistochemical detection of fibroblast activation markers on paraffin sections of urothelial carcinoma of the urinary bladder. a ASMA expression is regularly present in the carcinoma stroma myofibroblasts (T3a/G3 carcinoma) whereas b FAP is heterogeneously expressed in tumour cells and in stromal cells showing a cytoplasmic staining pattern (T3b/G3 carcinoma). c SDF-1 is strongly expressed in carcinoma cells but showed nearly no occurrence in stromal cells (T3b/G3 carcinoma). S100A4 (d) is detectable in tumour cells, stromal fibroblasts and lymphocytes (T4a/ G2-3 carcinoma) and PDGFRb (e) shows a more or less exclusive stromal staining (T3a/G3 carcinoma). (Hematoxylin counter staining, bars 100 lm in a and e, 50 lm in b-d) Histochem Cell Biol (2012) 138:847-860 853 supplementary material (Table S3 ). All statistically significant differences are given in Table 3 . This analysis revealed that the loss of membranous E-cadherin and the expression of its repressors in carcinoma cells showed a significant association to invasiveness of UBC, whereas only E-cadherin exhibited a statistically significant relation to metastasis. Among the investigated stromal activation markers, ASMA, S100A4, and PDGFRb showed an association to invasiveness whereas only S100A4 and PDGFRb were additionally correlated to metastasis. By means of Spearman-Rho rank correlation analysis, the relation of the immunohistochemical expression of E-cadherin and its repressors was correlated to the occurrence of stromal activation markers. All p values are provided as supplementary material (Table S4) . Statistically significant correlations are outlined in Table 4 . From these results, obvious interrelations seem to exist between ASMA expression and stromal Snail and Slug occurrence. Furthermore, ASMA expression showed a correlation to Slug in the cytoplasm and nuclei of tumour cells as well. In contrast, the carcinoma cell positivity for Zeb1 was strongly associated with the occurrence of S100A4 and PDGFRb in the tumour stroma. These data were in line with a relation to the loss of membranously expressed E-cadherin.
Characterization of different in vitro generated phenotypes of activated fibroblasts
Stimulation of hTERT-BJ1 fibroblasts with different growth factors resulting in different phenotypes of activated fibroblasts was performed in vitro. This cell culture model was valuable to investigate the functionally different effects of such activated fibroblasts. To characterize the fibroblast types, changes in mRNA expression of selected stromal activation markers were assessed by RT-PCR 3 days after stimulation compared to non-stimulated controls. Characterization was supplemented by an analysis of mRNA expression of oncofetal fibronectin isoforms (EDA ? and EDB ? fibronectins) known as functional important cell adhesion molecules, modulating fibroblast phenotype transition (Serini et al. 1998 ). In addition, stromal fibroblast-related fibronectin matrix remodelling represents a key step in the formation of an invasion promoting microenvironment.
As shown by the 40-DCT values, non-stimulated fibroblasts exhibited a moderate-to-high mRNA expression of the majority of proteins investigated (Fig. 3a) . The most pronounced mRNA upregulation could be seen for Snail, ASMA, FAP, as well as of the oncofetal EDA ? and EDB ? fibronectin variants in TGFb1 stimulated fibroblasts. With the exception of FAP, all other growth factors lead to unaltered or downregulated mRNA expression levels of both activation markers and fibronectin variants as well (Fig. 3b) . The TGFb1 mediated upregulation and PDGF-AB mediated down-regulation of ASMA could also be evidenced by immunocytochemistry. Furthermore, as revealed by Ki67 immunodetection, there were differences in the proliferative activity of PDGF-AB treated fibroblasts showing an obvious increased Ki67 expression and higher cellularity compared to aFGF treated fibroblasts that exhibited a diminution in Ki67 immunoreactivity ( Figure  S1 ). There were also markable differences in fibroblast morphology (data not shown). Tm tumour cell membrane, Tn tumour nucleus, Tc tumour cytoplasm, S stroma 
Effects of the different phenotypes of activated fibroblasts on invasion and EMT in vitro
To investigate the influence of the distinguishable fibroblast phenotypes on invasive capability and EMT phenomena in UBC, the cell line RT112 was used. RT112 cells exhibit an epithelial phenotype characterized by a strong immunohistochemical expression of E-cadherin and cytokeratin and a lack of vimentin and N-cadherin protein deposition (Fig. 4a ). Using these cells in an invasion assay with different fibroblast phenotypes as attractant cells, it could be shown that (1) invasion of RT112 strictly depended on the presence of fibroblasts, (2) TGFb1 and aFGF/TGFb1 stimulated fibroblasts induced a tremendous increase in the invasive capability, while (3) PDGF-AB and aFGF stimulated fibroblasts had the same invasion inducing effect compared to non-stimulated fibroblasts (Fig. 4b) .
To elucidate the effects of activated fibroblasts on the carcinoma cell phenotype transition and the relation to the invasive capability, additionally mRNA was selectively isolated from non-invasive and invasive cells and the mRNA expression of E-cadherin, Snail, Slug, Zeb1, N-cadherin, and vimentin was assessed as fold changes in relation to the non-invasive cells of invasion assays without fibroblasts (Fig. 5 ). There were no obvious changes in E-cadherin mRNA (data not shown). The most pronounced EMT effect with respect to the re-expression of N-cadherin and vimentin could be observed in the RT112 cells attracted by fibroblasts stimulated with aFGF or with aFGF/TGFb1. In case of these mesenchymal marker proteins, non-invasive and invasive cells showed the same pattern of expression levels. However, the invasive cells revealed an up to 200-fold increase in mRNA expression in comparison to their non-invasive counterpart. Interestingly, there were peculiar differences in the mRNA expression of E-cadherin repressors; in contrast to the non-invasive cells, invading RT112 cells showed a remarkable upregulation of Zeb1 mRNA with the strongest effect in cells attracted by aFGF stimulated fibroblasts.
Discussion
The present study was focused on the relation between fibroblast activation and EMT in UBC in situ and in vitro. As revealed by immunohistochemistry, among the investigated fibroblast activation markers ASMA, S100A4, and PDGFRb showed the most remarkable expression in the carcinoma stroma with a statistically significant correlation to invasiveness. With respect to ASMA and S100A4, these results go in line with recent findings by Matsumoto et al. (2007) and by Shimasaki et al. (2006) . Interestingly, an advanced invasive growth as well as metastatic disease is statistically significantly correlated to the occurrence of S100A4 and PDGFRb suggesting a special role of fibroblast expressing these markers for the development of an aggressive carcinoma cell phenotype. This is supported by recent findings reporting on a prognostic relevance of stromal PDGFRb expression in prostate and breast cancer (Paulsson et al. 2009; Hagglof et al. 2010 ). In addition, also for the development of a special fibroblast phenotype involved in cutaneous wound healing, a crucial role of PDGFRb signalling could be evidenced implicating a certain impact for the development of a migratory epithelial cell (Chang et al. 2004; Rajkumar et al. 2006) . With respect to these results, we postulate the existence of functionally different carcinoma-associated fibroblast (CAF) populations in UBC stroma with different effects on tumour cell behaviour. Hitherto it is unknown, if the differential expression of the investigated fibroblast activation markers represents primary different cell types, or consecutive stages in the process of myofibroblast transdifferentiation of the stromal fibroblasts. This important issue should be the object of further functional studies.
Because it could be shown that CAF are capable to induce EMT phenomena in carcinoma cells, we further investigated the relation of stromal activation to the immunohistochemical expression of E-cadherin and its repressors. First, we could demonstrate that there is a statistically significant correlation between the loss of membranous E-cadherin and invasiveness as well as nodal metastasis. This is in line with the results of several other groups evidencing the tumour biological and prognostic significance of aberrant E-cadherin expression (Byrne et al. 2001; Sun and Herrera 2004; Bryan et al. 2008; Shi et al. 2008; Wallerand et al. 2010; Hu et al. 2011; Lim et al. 2011) and speaks well for the representativeness of our study cohort. In addition, there are few carcinomas showing a strong membranous E-cadherin expression in association to a disseminated growth. Although the phenomenon must be the object of further studies also including an analysis of N-cadherin, we would like to suggest that this expression pattern seems to be associated to collective tumour cell invasion indicating that the ratio of E-cadherin down-regulation and N-cadherin and/or P-cadherin up-regulation may dictate the mode of invasion (Bryan and Tselepis 2010) . As a result of the correlative analysis, there is an obvious relation between stromal expression of S100A4 and/or PDGFRb, the loss of membranous E-cadherin and the expression of Zeb1 in tumour cells indicating a functional role of the S100A4
? /PDGFRb ? CAF phenotype in the epigenetic regulation of Zeb1 mediated down-regulation of E-cadherin. Our in situ results correspond to recent in vitro findings reporting on a crucial role of Zeb1 in the regulation of E-cadherin and invasiveness in UBC cells which is epigenetically regulated by members of the miR-200 family (Sayan et al. 2009; Kenney et al. 2011; Wiklund et al. 2011) . Although the relation of Zeb1 expression to clinical parameters is controversially discussed (Sayan et al. 2009; Kenney et al. 2011) , it seems to have at least a crucial role in mediating CAF induced carcinoma cell motility.
Furthermore, there is an obvious association of immunohistochemical ASMA expression in the carcinoma stroma and the occurrence of nuclear or cytoplasmic Slug. Recently, Slug expression has been reported to be associated with tumour growth and metastases in UBC in vitro, in situ, and in a xenograft model as well Yu et al. 2010) . Indeed, there is also a tendency for an increase in Slug with occurrence of metastases in our study. There are only a few investigations available from the literature reporting on the relation between the occurrence of ASMA-positive myofibroblasts and tumour progression in UBC and also in our current study a statistically significant correlation could not be proven. Nevertheless, there is valid evidence that stromal myofibroblast occurrence is strongly related to patient's outcome for other tumour entities (Marsh et al. 2010; Yamashita et al. 2010) . Therefore, we would like to postulate that the stromal myofibroblast phenotype may have supportive effects in the process of Slug-dependent carcinoma cell phenotype changes with an increase in malignancy also in UBC. However, this hypothesis has to be proven in further studies enrolling a larger number of patients. Moreover, there was also an obvious correlation of stromal Snail and Slug to the immunohistochemical expression of ASMA. This is in line with comparable findings for instance in head and neck carcinomas (Franz et al. 2009; Jouppila-Matto et al. 2011) and may either be indicative for the development of an activated and invasive stromal myofibroblast phenotype (Rowe et al. 2009 ) or may mark fully transdifferentiated EMT cells. Summarizing the in situ results, there is evidence of the existence of biologically distinguishable fibroblast populations in UBC stroma at least characterized by their expression of ASMA, PDGFRb, and S100A4. In addition, these fibroblasts seem to have varying effects on the expression of E-cadherin repressors. To elucidate the influence of different activated fibroblast phenotypes on invasive behaviour and the expression of E-cadherin repressors in UBC cells, we performed some in vitro studies. Immortalized human fibroblasts were stimulated with various growth factors and subsequently used as attractant cells in a Matrigel TM based invasion assay of RT112 cells. Although the UBC cell line RT112 was originally derived from a moderately differentiated invasive carcinoma, it is widely used as a model for superficial bladder cancer (Fujiyama et al. 2001) . Indeed, as also described by Davies et al. (1999) , the cells show a well established epithelial phenotype with abundant E-cadherin expression and low invasive capability without or with non-stimulated fibroblasts as attractant cells. Therefore, these cells are additionally a valuable model to investigate the relationship between fibroblast-induced changes in invasion and E-cadherin repressor expression in UBC. Although we were only partially able to mimic the above suggested activated fibroblast phenotypes in UBC stroma in vitro, we could demonstrate that they exert obvious different tumour biological effects. As expected, TGFb1 is a potent inductor of the myofibroblast phenotype characterized by the expression of ASMA and the co-regulator ED-A ? fibronectin (see also Serini et al. 1998 ). Interestingly, this is accompanied by an up-regulation of Snail which is in line with recent reports on a contribution of Snail to a migratory fibroblast phenotype (Rowe et al. 2009 ). As furthermore expected, PDGF-AB stimulation leads to fibroblast mitogenesis and down-regulation of ASMA as well as a diminution of immunohistochemically detectable PDGFRb (data not shown) (Dietrich et al. 1997; Chiarugi et al. 2002) . aFGF stimulation was performed because it has been reported recently that FGF1/FGFR3 signalling in fibroblasts leads to an increased potential to induce invasion of colon cancer cells (Henriksson et al. 2011 ). In congruence with recent studies available from the literature, we could show a slight up-regulation of FAP, no alterations of ASMA expression, and a reduced proliferative activity (Ramos et al. 2006; Henriksson et al. 2011) . TGFb1/aFGF co-stimulation was introduced because there is a reciprocal interaction of both growth factors during phenotype modulation in carcinoma cells as well as in fibroblasts (Thannickal et al. 1998; Ramos et al. 2010; Shirakihara et al. 2011) . Interestingly, the TGFb1-induced myofibroblast phenotype and the TGFb1/aFGF-generated fibroblast phenotype were the most potent attractant cells for RT112 invasion. In contrast, there is a completely different pattern in the up-regulation of E-cadherin repressors, Vimentin, and N-cadherin as hallmarks of EMT. Here, aFGF or TGFb1/aFGF-stimulated fibroblasts are the most potent inductors of Zeb1, the cadherin switch and a mesenchymal phenotype represented by vimentin. In congruence with the in situ results, it is not the ASMApositive myofibroblast phenotype which primarily induces these Zeb1 mediated EMT phenomena. Summarizing the results of the invasion assays, it could be suggested that there are indeed different fibroblast phenotypes with respect to there capability to induce carcinoma cell invasion and EMT as shown in situ, and that the development of an invasive carcinoma cell phenotype in UBC is not necessarily linked with EMT. The tumour biological and clinical relevance of this finding should be the object of further studies. However, the reciprocal interaction of a functional heterogeneous CAF population with the UBC cells should be considered as a reason for the variability in treatment response during targeted therapy.
